Is the use of albumin of value in the treatment of ascites in cirrhosis? the case in favour

Digestive and Liver Disease

Volumn 35, Issue 9, 2003, Pages 660-663

  Laffi, G ^a   Gentilini, P ^a   Romanelli, R G ^a   La Villa, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Albumin; Ascites; Cirrhosis; Diuretics; Hepatorenal syndrome

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; PLASMA SUBSTITUTE; SPIRONOLACTONE; ALBUMINOID;

ARTERIAL PRESSURE; ARTICLE; ASCITES; AUTONOMIC NERVOUS SYSTEM; CLINICAL TRIAL; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOALBUMINEMIA; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; MONOTHERAPY; ONCOTIC PRESSURE; OUTPATIENT; PARACENTESIS; PERITONITIS; PORTAL HYPERTENSION; PROBABILITY; QUALITY OF LIFE; SODIUM RETENTION; STARLING LAW; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; RANDOMIZED CONTROLLED TRIAL;

ALBUMINS; ASCITES; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; LIVER CIRRHOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 1542603605     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00384-0     Document Type: Article

References (19)

1. Arroyo V, Ginés P, Jiménez W, Rodés J. Ascites and renal dysfunction in hepatic cirrhosis. Pathogenesis, diagnosis, and treatment of ascites in cirrhosis. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J, editors, Oxford textbook of clinical hepatology, Oxford: Oxford University Press; 1999, pp. 697-731.
2. Gentilini P, La Villa G, Laffi G, Buzzelli G, Pinzani M, Cominelli F, et al. Sodium retention in cirrhosis: aspects of pathophysiology and treatment. Front Gastrointest Res 1986;9:203-18.
3. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151-7.
4. Levy M. Pathophysiology of ascites formation. In: Epstein M, editor, The kidney in liver disease, 4th ed., Philadelphia, PA: Hanley and Belfus; 1996, pp. 179-220.
5. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-7.
6. Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997;17:163-75.
7. Erstad BL, Gales BJ, Rappaport WD. The use of albumin in clinical practice. Arch Intern Med 1991;151:901-11.
8. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. Br Med J 1998;317:235-40.
9. Vermeulen LC, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloids, and crystalloid solutions. Arch Intern Med 1995;155:373-9.
10. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998;27:264-72.
11. Gines P, Schrier RW. Hepatorenal syndrome and renal dysfunction associated with liver disease. In: Schrier RW, Gottschalk CW, editors, Diseases of the kidney, 6th ed, Boston, MA: Little Brown and Company; 1997, pp. 2099-127.
12. Frommer JP, Wesson D, Eknoyan G. Side effects and complications of diuretic therapy. In: Eknoyan G, Martinez-Maldonado M, editors, The physiological basis of diuretic therapy in clinical medicine, Orlando, FL: Grune and Stratton; 1986, pp. 293-309.
13. Sherlock S, Senewiratne B, Scott A, Walker JG. Complications of diuretic therapy in hepatic cirrhosis. Lancet 1966;1:1049-53.
14. Gentilini P, La Villa G, Marra F, Carloni V, Melani L, Foschi M, et al. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. J Hepatol 1996;25:481-90.
15. Losowsky MS, Atkinson M. Intravenous albumin in the treatment of diuretic-resistant ascites in portal cirrhosis. Lancet 1961;2:386-9.
16. Wilkinson P, Sherlock S. The effect of repeated albumin infusion in patients with cirrhosis. Lancet 1962;11:1125-9.
17. Fattore G, Lazzaro C. Analisi dei costi della somministrazione di albumina umana nel paziente cirrotico con ascite. Medicosan 2001;40:53-65.
18. Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999;30:639-45.
19. Vizzutti F, Romanelli RG, Casini-Raggi V, Montalto P, Pastacaldi S, Pinzani M, et al. Diuretic and natriuretic effects of long-term albumin infusion in patients with cirrhosis and ascites. A randomized controlled study. J Hepatol 2001;34(suppl. 1):17.